UniProt Q9UIK4 · PDB · AlphaFold · Substrate: ZIPtide + Ca-CaM · Clone: full catalyticmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Alectinib | 88.7% | 11.3% | 95.49 | 0.651 |
| 2 | Fedratinib | 74.2% | 25.8% | 96.21 | 0.576 |
| 3 | Brigatinib | 65.0% | 35.0% | 82.96 | 0.513 |
| 4 | Abemaciclib | 51.6% | 48.4% | 91.48 | 0.563 |
| 5 | Sunitinib | 43.4% | 56.6% | 91.73 | 0.524 |
| 6 | Gilteritinib | 43.0% | 57.0% | 88.97 | 0.506 |
| 7 | Pacritinib | 35.3% | 64.7% | 88.64 | 0.452 |
| 8 | Nintedanib | 34.2% | 65.8% | 90.23 | 0.608 |
| 9 | Palbociclib | 33.1% | 66.9% | 98.75 | 0.673 |
| 10 | Ribociclib | 31.6% | 68.4% | 99.25 | 0.729 |
| 11 | Infigratinib | 25.7% | 74.3% | 98.24 | 0.710 |
| 12 | Ruxolitinib | 23.6% | 76.4% | 98.25 | 0.592 |
| 13 | Midostaurin | 22.3% | 77.7% | 78.64 | 0.500 |
| 14 | Baricitinib | 20.6% | 79.4% | 97.99 | 0.616 |
| 15 | Rabusertib | 20.3% | 79.7% | 98.74 | 0.687 |
| 16 | Leniolisib | 20.1% | 79.9% | 100.00 | 0.604 |
| 17 | Mitapivat | 18.8% | 81.2% | 100.00 | 0.625 |
| 18 | Abrocitinib | 18.7% | 81.3% | 99.50 | 0.581 |
| 19 | Paxalisib | 15.4% | 84.6% | 99.75 | 0.609 |
| 20 | Umbralisib | 14.9% | 85.1% | 98.74 | 0.670 |
Paralog block
DAPK1, DAPK2
EMT expression
- Mesenchymal log2(TPM+1): 1.26
- Epithelial log2(TPM+1): 1.53
- Fold change: -0.27
- Status: No significant change
High-confidence drugs
- Alectinib — inh 88.7% · KISS 30.23
- Fedratinib — inh 74.2% · KISS 13.60
- Brigatinib — inh 65.0% · KISS -4.68
Selectivity landscape vs inhibition on DAPK2
Each point is one of the 92 approved drugs; color = inhibition % on DAPK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…